Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

X4 Pharmaceuticals nets $80.2mm through public offering

Executive Summary

X4 Pharmaceuticals Inc. (treatments for rare diseases and cancers) netted $80.2mm through a public offering. The company sold 5.67mm common shares at $11, and issued pre-funded warrants to purchase 2.13mm shares at a price of $10.999 per pre-funded warrant. Investors also received five-year Class A warrants buy 3.9mm common at an exercise price of $13.20. Proceeds will enable the company to support a Phase III pivotal trial of mavorixafor in patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome; begin a Phase I trial with mavorixafor for severe congenital neutropenia; initiate a Phase I/II study with mavorixafor in Waldenström macroglobulinemia; and to fund additional R&D and corporate needs.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies